Back to Search
JERRY KOLESAR, D.M.D
D.M.D
General Practice Dentistry
NPI: 1912072745Individual
Specialties, Licenses & Credentials
General Practice DentistryPrimary
Dentist — General Practice
Code: 1223G0001X
036955(CA)
Research & Publications (20)
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.
PMID 18941749·Cancer Chemother Pharmacol·2009
4-observational
Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine.
PMID 18061679·J Inorg Biochem·2008
8-other
A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.
PMID 19238328·Invest New Drugs·2010
3-trial
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
PMID 18795290·Cancer Chemother Pharmacol·2009
3-trial
A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.
PMID 19082825·Cancer Chemother Pharmacol·2009
3-trial
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
PMID 19347984·J Thorac Oncol·2009
3-trial
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
PMID 19129971·Invest New Drugs·2009
3-trial
Stability of alemtuzumab for low-dose induction and test doses.
PMID 19191774·Am J Transplant·2009
8-other
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
PMID 19634157·Cancer·2009
3-trial
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
PMID 18668698·Hematol Oncol·2009
3-trial
Mutation in TACO1, encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset Leigh syndrome.
PMID 19503089·Nat Genet·2009
8-other
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
PMID 18701186·Lung Cancer·2009
8-other
Hydroxyurea induced acute elevations in liver function tests.
PMID 18337443·J Oncol Pharm Pract·2008
5-case
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
PMID 18407955·Ann Oncol·2008
3-trial
A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.
PMID 18451239·Clin Cancer Res·2008
3-trial
Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
PMID 18574011·Am J Health Syst Pharm·2008
6-review
Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
PMID 19194367·Clin Adv Hematol Oncol·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1122 N BRAND BLVD STE 102
GLENDALE, CA 91202 - Phone
- (818) 242-2667
Quick Facts
- NPI
- 1912072745
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile